Beam Therapeutics is a biotechnology company committed to creating a new class of precision genetic medicines based on our proprietary base editing technology, with a vision of providing life-long cures to patients suffering from serious diseases.
Recent Press Releases
May 9, 2022
Beam Therapeutics Announces Pipeline and Business Highlights and Reports First Quarter 2022 Financial Results
May 4, 2022
May 2, 2022
Beam Therapeutics to Present New Preclinical Data from Base Editing Pipeline at ASGCT 25th Annual Meeting